FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1915205035> ?p ?o ?g. }

• W1915205035 endingPage "39" @default.
• W1915205035 startingPage "2729" @default.
• W1915205035 abstract "This Phase I/II radioimmunotherapy study was carried out to determine the maximum tolerated dose (MTD) and therapeutic potential of 131I-G250. Thirty-three patients with measurable metastatic renal cell carcinoma were treated. Groups of at least three patients received escalating amounts of 1311I (30, 45, 60, 75, and 90 mCi/m2) labeled to 10 mg of mouse monoclonal antibody G250, administered as a single i.v. infusion. Fifteen patients were studied at the MTD of activity. No patient had received prior significant radiotherapy; one had received prior G250. Whole-body scintigrams and single-photon emission computed tomography images were obtained in all patients. There was targeting of radioactivity to all known tumor sites that were > or =2 cm. Reversible liver function test abnormalities were observed in the majority of patients (27 of 33 patients). There was no correlation between the amount of 131I administered or hepatic absorbed radiation dose (median, 0.073 Gy/mCi) and the extent or nature of hepatic toxicity. Two of the first six patients at 90 mCi/m2 had grade > or =3 thrombocytopenia; the MTD was determined to be 90 mCi/m2 131I. Hematological toxicity was correlated with whole-body absorbed radiation dose. All patients developed human antimouse antibodies within 4 weeks posttherapy; retreatment was, therefore, not possible. Seventeen of 33 evaluable patients had stable disease. There were no major responses. On the basis of external imaging, 131I-labeled mouse monoclonal antibody G250 showed excellent localization to all tumors that were > or =2 cm. Seventeen of 33 patients had stable disease, with tumor shrinkage observed in two patients. Antibody immunogenicity restricted therapy to a single infusion. Studies with a nonimmunogenic G250 antibody are warranted." @default.
• W1915205035 created "2016-06-24" @default.
• W1915205035 creator A5009949949 @default.
• W1915205035 creator A5015396908 @default.
• W1915205035 creator A5023679883 @default.
• W1915205035 creator A5031242402 @default.
• W1915205035 creator A5036269467 @default.
• W1915205035 creator A5039475847 @default.
• W1915205035 creator A5048535871 @default.
• W1915205035 creator A5052930362 @default.
• W1915205035 creator A5056620057 @default.
• W1915205035 creator A5066901026 @default.
• W1915205035 creator A5070626557 @default.
• W1915205035 creator A5074348602 @default.
• W1915205035 creator A5075079547 @default.
• W1915205035 creator A5078161354 @default.
• W1915205035 creator A5078312966 @default.
• W1915205035 creator A5085157766 @default.
• W1915205035 creator A5089344430 @default.
• W1915205035 date "1998-11-01" @default.
• W1915205035 modified "2023-09-26" @default.
• W1915205035 title "Phase I/II radioimmunotherapy trial with iodine-131-labeled monoclonal antibody G250 in metastatic renal cell carcinoma." @default.
• W1915205035 cites W105233035 @default.
• W1915205035 cites W1642037236 @default.
• W1915205035 cites W1749279251 @default.
• W1915205035 cites W1866826474 @default.
• W1915205035 cites W1967889416 @default.
• W1915205035 cites W1988964865 @default.
• W1915205035 cites W2003559448 @default.
• W1915205035 cites W2016292927 @default.
• W1915205035 cites W2022101147 @default.
• W1915205035 cites W2030522563 @default.
• W1915205035 cites W2031501898 @default.
• W1915205035 cites W2084377890 @default.
• W1915205035 cites W2084628122 @default.
• W1915205035 cites W2089514388 @default.
• W1915205035 cites W2095637914 @default.
• W1915205035 cites W2108079488 @default.
• W1915205035 cites W2138463196 @default.
• W1915205035 cites W2149612540 @default.
• W1915205035 cites W2222638000 @default.
• W1915205035 cites W2254396289 @default.
• W1915205035 cites W2396848493 @default.
• W1915205035 cites W2397996199 @default.
• W1915205035 cites W2399047173 @default.
• W1915205035 cites W2399474082 @default.
• W1915205035 cites W2410777658 @default.
• W1915205035 cites W2414415606 @default.
• W1915205035 cites W2416385708 @default.
• W1915205035 cites W2460794217 @default.
• W1915205035 cites W366950334 @default.
• W1915205035 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9829736" @default.
• W1915205035 hasPublicationYear "1998" @default.
• W1915205035 type Work @default.
• W1915205035 sameAs 1915205035 @default.
• W1915205035 citedByCount "55" @default.
• W1915205035 countsByYear W19152050352012 @default.
• W1915205035 countsByYear W19152050352013 @default.
• W1915205035 countsByYear W19152050352016 @default.
• W1915205035 countsByYear W19152050352017 @default.
• W1915205035 countsByYear W19152050352021 @default.
• W1915205035 countsByYear W19152050352022 @default.
• W1915205035 countsByYear W19152050352023 @default.
• W1915205035 crossrefType "journal-article" @default.
• W1915205035 hasAuthorship W1915205035A5009949949 @default.
• W1915205035 hasAuthorship W1915205035A5015396908 @default.
• W1915205035 hasAuthorship W1915205035A5023679883 @default.
• W1915205035 hasAuthorship W1915205035A5031242402 @default.
• W1915205035 hasAuthorship W1915205035A5036269467 @default.
• W1915205035 hasAuthorship W1915205035A5039475847 @default.
• W1915205035 hasAuthorship W1915205035A5048535871 @default.
• W1915205035 hasAuthorship W1915205035A5052930362 @default.
• W1915205035 hasAuthorship W1915205035A5056620057 @default.
• W1915205035 hasAuthorship W1915205035A5066901026 @default.
• W1915205035 hasAuthorship W1915205035A5070626557 @default.
• W1915205035 hasAuthorship W1915205035A5074348602 @default.
• W1915205035 hasAuthorship W1915205035A5075079547 @default.
• W1915205035 hasAuthorship W1915205035A5078161354 @default.
• W1915205035 hasAuthorship W1915205035A5078312966 @default.
• W1915205035 hasAuthorship W1915205035A5085157766 @default.
• W1915205035 hasAuthorship W1915205035A5089344430 @default.
• W1915205035 hasConcept C126322002 @default.
• W1915205035 hasConcept C126894567 @default.
• W1915205035 hasConcept C159654299 @default.
• W1915205035 hasConcept C203014093 @default.
• W1915205035 hasConcept C2776146153 @default.
• W1915205035 hasConcept C2777472916 @default.
• W1915205035 hasConcept C29730261 @default.
• W1915205035 hasConcept C2989005 @default.
• W1915205035 hasConcept C509974204 @default.
• W1915205035 hasConcept C542903549 @default.
• W1915205035 hasConcept C71924100 @default.
• W1915205035 hasConcept C90924648 @default.
• W1915205035 hasConceptScore W1915205035C126322002 @default.
• W1915205035 hasConceptScore W1915205035C126894567 @default.
• W1915205035 hasConceptScore W1915205035C159654299 @default.
• W1915205035 hasConceptScore W1915205035C203014093 @default.
• W1915205035 hasConceptScore W1915205035C2776146153 @default.

• next